Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review

Date: April 2, 2014
Pages: 48
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C77D6867747EN
Leaflet:

Download PDF Leaflet

Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review
Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company. It develops and commercializes integrated portfolio of oncology products. The company's product pipeline include Pixuvri (pixantrone dimaleate), for the treatment of non-Hodgkin lymphoma (NHL); tosedostat, a Phase II clinical trial compound for the treatment of acute myeloid leukemia (AML) and myelodysplasia (MDS); brostallicin, for the treatment of triple-negative metastatic breast cancer and is in Phase II; Opaxio (paclitaxel poliglumex), a Phase III compound, for the treatment of solid tumors; and pacritinib, for the treatment of myelofibrosis which is in Phase III clinical trial.

Cell Therapeutics, Inc. Key Recent Developments

Mar 04, 2014: Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Feb 03, 2014: Cell Therapeutics Appoints Karen Ignagni to Board of Directors
Jan 14, 2014: Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Dec 18, 2013: Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
Nov 15, 2013: Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Cell Therapeutics, Inc. - Key Facts
Cell Therapeutics, Inc. - Key Employees
Cell Therapeutics, Inc. - Key Employee Biographies
Cell Therapeutics, Inc. - Major Products and Services
Cell Therapeutics, Inc. - Pharmaceutical Pipeline Products Data
Cell Therapeutics, Inc., Pipeline Products by Therapy Area
Cell Therapeutics, Inc., Pipeline Products by Development Phase
Cell Therapeutics, Inc. - History
Cell Therapeutics, Inc. - Company Statement
Cell Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Cell Therapeutics, Inc. - Business Description
Cell Therapeutics, Inc. - Corporate Strategy
Cell Therapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
Cell Therapeutics, Inc. - Strengths
Strength - Strong Technological Base
Strength - Collaborative Agreements
Cell Therapeutics, Inc. - Weaknesses
Weakness - Lack of Manufacturing Facilities
Weakness - History of losses
Weakness - Legal Proceedings
Cell Therapeutics, Inc. - Opportunities
Opportunity - Strong Base of Pipeline Products
Opportunity - Changing Demographics
Opportunity - Market Potential: Cancer
Cell Therapeutics, Inc. - Threats
Threat - Stringent Government Regulations
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Cell Therapeutics, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Cell Therapeutics, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Cell Therapeutics, Inc., Recent Developments
Mar 04, 2014: Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Feb 03, 2014: Cell Therapeutics Appoints Karen Ignagni to Board of Directors
Jan 14, 2014: Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Dec 18, 2013: Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
Nov 15, 2013: Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
Oct 30, 2013: Cell Therapeutics Reports Third Quarter 2013 Financial Results
Oct 23, 2013: Cell Therapeutics to Report Third Quarter Financial Results after Market on October 30, 2013
Oct 14, 2013: Cell Therapeutics Adds Three Leaders in Blood Cancer Research and Development to Scientific Advisory Board
Sep 18, 2013: Cell Therapeutics to present at upcoming investor conferences
Jul 31, 2013: Cell Therapeutics Reports Second Quarter 2013 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Cell Therapeutics, Inc., Key Facts
Cell Therapeutics, Inc., Key Employees
Cell Therapeutics, Inc., Key Employee Biographies
Cell Therapeutics, Inc., Major Products and Services
Cell Therapeutics, Inc., Number of Pipeline Products by Therapy Area
Cell Therapeutics, Inc., Number of Pipeline Products by Development Stage
Cell Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase
Cell Therapeutics, Inc., History
Cell Therapeutics, Inc., Subsidiaries
Cell Therapeutics, Inc., Key Competitors
Cell Therapeutics, Inc., Ratios based on current share price
Cell Therapeutics, Inc., Annual Ratios
Cell Therapeutics, Inc., Interim Ratios
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Cell Therapeutics, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Cell Therapeutics, Inc., Pipeline Products by Therapy Area
Cell Therapeutics, Inc., Pipeline Products by Development Phase
Cell Therapeutics, Inc., Performance Chart (2009 - 2013)
Cell Therapeutics, Inc., Ratio Charts
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Skip to top


Ask Your Question

Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: